Please assess the completion status of the following clinical trial:

Trial Title: NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provides written informed consent~* Diagnosed with mCRPC and painful bone metastases, referred for Xofigo (radium Ra 223 dichloride)~* Able to remain still for duration of the imaging procedure (about one hour)~Exclusion Criteria:~* Metallic implants

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (18F NaF/18F FDG PET/MRI, contrast-enhanced MRI) (Type: EXPERIMENTAL): Patients receive 18F NaF and 18F FDG IV over 30 seconds-1 minute and then undergo PET/MRI and contrast-enhanced MRI after 45-60 minutes. Patients undergo imaging at baseline, after course 3 (12 weeks), and after course 6 (24 weeks) of treatment with Ra-223.

Based on this trial design, predict the completion outcome and termination type (if applicable).